mRNA technology has opened the door to a new world of medicines. The platform technology is adaptable and allows for a fast, scalable, and thus flexible manufacturing. These properties specifically make this novel drug class not only ideal to tackle a pandemic but is well suited for the application for high precision medicines. Individualized mRNA-based cancer immunotherapies are one approach to address the individual genetic mark up of tumors and have the potential to close a gap in cancer treatment. While the technology is one important pillar, manufacturing is key to translate the technology and drug design into the final drug product. BioNTech has developed an on-demand manufacturing process to design and manufacture individualized mRNA-based cancer vaccines based on its iNeST platform in clinically relevant timeframes, also by employing next-generation sequencing and AI-based bioinformatic neoantigen discovery. Today, this expertise and know-how has been incorporated into a modular and turnkey manufacturing solution based on a container that can be easily shipped and built up to support a decentralized and scalable mRNA vaccine production that addresses local needs.